Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Gemcitabine and Cisplatin vs Gemcitabine and Cisplatin in Unresectable Advanced Intrahepatic Cholangiocarcinoma
ChiCTR2500107754Phase 4Not yet recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Aug 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of pembrolizumab in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoints: Overall survival and Immune microenvironment indicators. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2500107754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107754.